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Abstract
Background: In Japan, high incidences of interstitial lung disease (ILD) and ILD-related deaths have
been reported among gefitinib-treated patients with non-small cell lung cancer (NSCLC). We
investigated the efficacy of gefitinib, the incidence of ILD and risk factors for ILD in these patients.
Findings: We obtained patient data retrospectively using questionnaires sent to 22 institutions.
We asked for demographic and clinical data on NSCLC patients for whom gefitinib treatment had
begun between July 2002 and February 2003. Data from a total of 526 patients were analyzed. The
patient characteristics were as follows: 64% male, 69% with adenocarcinoma, 61% with a
performance score of 0–1, and 5% with concurrent interstitial pneumonitis. The objective response
proportion was 80/439 (18.2%; 95% CI: 14.7–22.0). ILD developed in 17 patients (3.2%; 95% CI 1.9–
5.1%), of whom 7 died. According to multivariate analysis, female sex, history of prior
chemotherapy, low absolute neutrophil count before gefitinib treatment, and adenocarcinoma
histology were associated with response to gefitinib treatment. None of the factors we evaluated
were associated with the development of ILD.
Conclusion:  The results of this study are consistent with previously published values for
treatment response proportions and incidence of ILD during gefitinib treatment in Japanese
patients. Future studies should be aimed at identifying factors indicating that a patient has a high
probability of receiving benefit from gefitinib and a low risk of developing ILD.
Background
In most industrialized countries, non-small cell lung can-
cer (NSCLC) is the leading cause of death from cancer [1].
At the time of diagnosis, the majority of NSCLC patients
have advanced disease that is not amenable to curative
approaches, so NSCLC is associated with a poor progno-
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sis. Platinum-based chemotherapy provides a survival
benefit of limited duration [2], and combinations of
newer active agents (such as gemcitabine and paclitaxel)
with platinum have produced further improvement in
survival [3,4]. Docetaxel has been approved as a second-
line chemotherapy agent on the basis of randomized trials
involving patients in whom first-line chemotherapy was
unsuccessful, but the objective response proportions to
docetaxel are only 5–10%, and treatment is associated
with only a modest survival benefit [5,6].
Gefitinib is an orally active selective inhibitor of the epi-
dermal growth factor receptor (EGFR) tyrosine kinase and
has been found to have antitumor activity in patients with
advanced NSCLC who have undergone prior treatment.
According to several multicenter phase I trials [7-9],
diarrhea, skin rashes, and nausea are common adverse
events associated with gefitinib treatment, but most of
these adverse events are mild. Based on the results of two
large-scale multicenter phase II studies (IDEAL 1 and 2;
Iressa Dose Evaluation in Advanced Lung Cancer) [10,11],
in July 2002 gefitinib was approved in Japan for the treat-
ment of inoperable or recurrent NSCLC. However, since
approval, a number of deaths due to gefitinib-induced
interstitial lung disease (ILD) have been reported [12,13],
and the high incidences of ILD and associated mortality
have become a matter of great concern in Japan. Risk-ben-
efit assessments have become critical in the use of gefit-
inib. We report here the results of a retrospective study
conducted by the Japan Multinational Trial Organization
(JMTO: http://www.jmto.org/) to investigate the response
proportion, factors predicting response, and the incidence
of and risk factors for ILD in gefitinib-treated NSCLC
patients.
Methods
Patients with histologically or cytologically confirmed
NSCLC of any clinical or pathological stage, who began
taking gefitinib between July 2002 and February 2003,
were eligible for inclusion in the study. We obtained
patient data using questionnaires sent to 22 institutions,
and retrospectively analyzed the information provided in
the returned questionnaires, including laboratory find-
ings. The study protocol (JMTO LC03-02) was approved
by the ethics committees of JMTO and the participating
institutions.
Baseline assessments included age, sex, histological type
of NSCLC, clinical or pathological stage of cancer at diag-
nosis (using the current TNM classification system [14]),
Eastern Cooperative Oncology Group (ECOG) perform-
ance status (PS), history of smoking before starting gefit-
inib treatment, medical history (including prior
anticancer therapy), concurrent pulmonary disease (e.g.
interstitial pneumonitis or pulmonary emphysema), and
laboratory findings (complete blood cell count, blood
biochemistry, arterial blood gas analysis data). Diagnoses
of concurrent pulmonary disease were made by each insti-
tution on a clinical basis.
The endpoints of this study were response to gefitinib
treatment or occurrence of a serious adverse event during
gefitinib treatment or death due to the serious adverse
event. Adverse events were evaluated using the National
Cancer Institute Common Toxicity Criteria (NCI-CTC),
version 2.0, and a serious adverse event was defined as
being an NCI-CTC grade 4 adverse event, or any experi-
ence that resulted in death, was life-threatening, required
inpatient hospitalization or prolongation of existing hos-
pitalization, resulted in persistent or significant disability/
incapacity, or caused a congenital anomaly/birth defect,
according to the definition published by the International
Conference on Harmonisation of Technical Requirements
for Registration of Pharmaceuticals for Human Use [15].
In this study, ILD was assumed to be interstitial pneumo-
nitis as diagnosed by each institution on a clinical basis.
If patients had measurable disease, tumor response was
assessed on the basis of medical records, and if not men-
tioned in the medical records, the Response Evaluation
Criteria in Solid Tumors (RECIST) [16] or the World
Health Organization (WHO) criteria [17] were used for
assessment. The objective response was calculated as the
proportion of patients with a complete or partial
response.
Associations between serious adverse events or objective
response and patient characteristics were assessed using a
logistic regression model. Odds ratios (ORs) and 95%
confidence intervals (CIs) were estimated using univariate
analysis, and a backward elimination procedure was used
to identify significant predictors in the multivariate analy-
sis. Because of the comparability of the ORs, the units
used to measure absolute neutrophil count and lactate
dehydrogenase (LDH) level were Log transformed. Predic-
tive response probabilities were estimated based on a final
multivariate logistic regression model for evaluating asso-
ciations between response and ILD occurrence. All statis-
tical analyses were carried out using SAS version 8.02 (SAS
Institute, Cary NC, USA).
Results
Patient characteristics
A total of 536 patients were enrolled in this study, of
which 526 patients were eligible for analysis (10 patients
were excluded from analysis because they began taking
gefitinib before July 2002 or after February 2003). The
patient characteristics and laboratory findings are summa-
rized in Table 1.BMC Research Notes 2009, 2:157 http://www.biomedcentral.com/1756-0500/2/157
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Table 1: Patient characteristics (n = 526).
Characteristic No. patients % patients Mean (± SD)
Age (years) 526 66.2
(range 27–91)
Sex
Male 336 64
Female 190 36
Histological type
Adenocarcinoma 360 69
Squamous cell carcinoma 123 23
Other 43 8
History of smoking
No 170 32
Yes 319 61
Unknown 37 7
ECOG performance status
0–1 321 61
2–4 191 36
Unknown 14 3
Concurrent interstitial pneumonitis
No 500 95
Yes 26 5
Concurrent pulmonary emphysema
No 447 85
Yes 77 15
Unknown 2< 1
History of pulmonary tuberculosis
No 491 93
Yes 34 7
Unknown 1< 1
Prior surgery for lung cancer
No 337 64
Yes 189 36
Prior chemotherapy for lung cancer
No 115 22
Yes 411 78
Prior thoracic radiotherapy for primary lung cancer
No 330 63
Yes 194 37
Unknown 2< 1
Concurrent chemotherapy with agent other than gefitinib
No 485 92
Yes 41 8
Thoracic radiotherapy concurrent with or after gefitinib treatment
No 478 91
Yes 48 9BMC Research Notes 2009, 2:157 http://www.biomedcentral.com/1756-0500/2/157
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The mean patient age was 66.2 years (range 27–91 years).
A total of 336 patients (64%) were male, 360 patients
(69%) had adenocarcinoma, and 319 patients (61%)
were current or former smokers. In 26 patients (4.9%),
NSCLC was accompanied by concurrent interstitial pneu-
monitis. Gefitinib was given as a first-line chemothera-
peutic agent in 115 patients.
With respect to the laboratory findings before gefitinib
treatment, absolute neutrophil count, aspartate ami-
notransferase (AST) level, alanine aminotransferase (ALT)
level, and LDH level were reported for 485, 487, 515, and
495 patients, respectively (Table 1).
Response to treatment
For 439 patients (83%), tumor response was reported and
evaluable. Complete and partial responses were observed
for 7 and 73 patients, respectively. The objective response
proportion was 80/439 (18.2%; 95% CI: 14.7–22.0), and
the disease control proportion, which was the objective
response plus the proportion of patients with stable dis-
ease, was 237/439 (54.0%).
Factors predicting tumor response
The association between tumor response and various clin-
ical factors was assessed using logistic regression. In the
univariate analysis (Table 2), sex, histological type, his-
tory of smoking, concurrent pulmonary emphysema, his-
tory of prior chemotherapy, high absolute neutrophil
count, low LDH level, and high serum albumin level were
found to be associated with tumor response (p < 0.1). In
the multivariate analysis (Table 3), female sex (OR: 4.35;
95% CI: 2.40–7.90; p < 0.001), history of prior chemo-
therapy (OR: 0.34; 95% CI: 0.18–0.65; p = 0.001), high
absolute neutrophil count (OR: 0.85 per 1000/μL; 95%
CI: 0.75–0.93; p = 0.017), and adenocarcinoma histology
(OR: 2.35; 95% CI: 1.03–5.35; p = 0.043) were statisti-
cally significantly associated with tumor response.
ILD and other serious adverse events
Serious adverse events occurred during gefitinib treatment
in 66 of 526 patients. ILD developed in 17 patients (3.2%;
95% CI: 1.9%–5.1%), 7 (41%) of whom died during
treatment. Hepatic dysfunction occurred in seven
patients, one of whom died during treatment. Other seri-
ous adverse events included skin rash, diarrhea, aspiration
pneumonia, perforative peritonitis, acute enteritis, con-
vulsion, epilepsy, cancerous pain.
Analysis of factors affecting ILD
The association between ILD and various clinical factors
was evaluated using logistic regression. In the univariate
analysis, none of the factors we evaluated were found to
be associated with the development of ILD, including sex,
history of smoking, concurrent interstitial pneumonitis,
history of prior chemotherapy, or poor ECOG PS.
Analysis of the relation between response and ILD
We assessed the association between response and ILD
occurrence. When the predictive probability of a response
was estimated based on related factors (sex, history of
prior chemotherapy, absolute neutrophil count, and his-
tology) for each patient, no association between response
probability and occurrence of ILD was detected (chi-
square test, p = 0.379) (Figure 1). When the probability of
a response was 0–0.10, the incidence of ILD was 3.8% (8/
211, 95% CI: 1.7%–7.3%), and when the probability was
above 0.30, the incidence was 5.3% (6/114, 95% CI:
2.0%–11.1%).
Discussion
In the present study, the gefitinib response proportion
was 18.2%, which is similar to values determined in other
studies and clinical trials [10,18,19]. The response pro-
portion among patients with a history of prior chemother-
apy was 15.5%, which was somewhat higher than values
observed in clinical trials of docetaxel chemotherapy for
previously treated NSCLC patients (10.8% and 7.1%)
[5,6].
In this study, female sex, no history of prior chemother-
apy, low absolute neutrophil count, and adenocarcinoma
histology were associated with tumor response. There
have been a number of prior studies of the predictive fac-
tors for tumor response in gefitinib-treated NSCLC
patients in Japan [20-24], and results of these are summa-
rized in Table 4. Although female sex and adenocarci-
noma histology have also been found to be associated
with tumor response in other studies, absence of prior
chemotherapy and low absolute neutrophil have not. The
Absolute neutrophil count (/μL) 485 4786 (± 3331)
Eosinophil count (/μL) 483 163 (± 181)
Creatinine level (mg/dL) 496 0.77 (± 0.44)
Platelet count (×104/μL) 515 25.8 (± 10.3)
Albumin level (g/dL) 424 3.67 (± 0.58)
Aspartate aminotransferase level (IU/L) 487 25 (± 20)
Alanine aminotransferase level (IU/L) 515 23 (± 25)
Lactate dehydrogenase level (IU/L) 495 279 (± 318)
Table 1: Patient characteristics (n = 526). (Continued)BMC Research Notes 2009, 2:157 http://www.biomedcentral.com/1756-0500/2/157
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Table 2: Predictive factors for tumor response and risk factors associated with ILD (univariate analysis)
Factor Response
proportion (%)
Odds
ratio (95% CI)
p-value Incidence of
ILD (%)
Odds ratio
(95% CI)
p-value
Age - 1.01 (0.98–1.03) 0.644 1.00 (0.95–1.04) 0.823
Sex
Male 8.4 1 - 2.7 1 -
Female 34.3 5.68 (3.33–9.69) <0.001 4.2 1.60 (0.61–4.21) 0.344
Histological type
Non-adenocarcinoma 6.0 1 - 3.6 1 -
Adenocarcinoma 23.6 4.86 (2.27–10.42) <0.001 3.1 0.84 (0.31–2.33) 0.737
History of smoking
Yes 10.5 1 - 3.1 1 -
No 33.8 4.33 (2.57–7.29) <0.001 4.1 1.33 (0.50–3.57) 0.573
ECOG performance status
2–4 14.4 1 - 2.6 1 -
0–1 20.3 1.51 (0.89–2.59) 0.129 3.6 1.39 (0.48–4.00) 0.549
Concurrent interstitial pneumonitis
No 18.9 1 - 3.2 1
Yes 5.0 0.23 (0.03–1.72) 0.151 3.8 1.21 (0.15–9.49)
Concurrent pulmonary emphysema
No 19.9 1 - 3.1 1
Yes 7.1 0.31 (0.11–0.88) 0.028 3.9 1.25 (0.35–4.47)
Prior surgery
No 16.0 1 - 3.6 1 -
Yes 22.2 1.49 (0.91–2.44) 0.111 2.6 0.74 (0.26 -2.12) 0.571
Prior chemotherapy
No 28.6 1 - 2.6 1 -
Yes 15.5 0.46 (0.27–0.79) 0.005 3.4 1.32 (0.37–4.66) 0.670
Prior thoracic radiotherapy
No 19.3 1 - 3.9 1 -
Yes 16.6 0.83 (0.50–1.38) 0.468 2.1 0.51 (0.17–1.60) 0.250
Concurrent chemotherapy with
agent other than gefitinib
No 17.3 1 - 3.5 - -
Yes 28.6 1.91 (0.88–4.15) 0.103 0 - -
Thoracic radiotherapy concurrent
with or after gefitinib treatment
No 18.8 1 - 3.1 1 -
Yes 12.8 0.64 (0.24–1.69) 0.364 4.2 1.34 (0.30–6.05) 0.702
Absolute neutrophil count * - 0.84 (0.75–0.95) 0.004 - 0.96 (0.81–1.14) 0.609
Aspartate aminotransferase level ** - 1.00 (0.99–1.01) 0.967 - 0.99 (0.95–1.03) 0.635
Lactate dehydrogenase level *** - 0.82 (0.65–1.03) 0.085 - 0.95 (0.71–1.27) 0.724
Albumin level **** - 1.54 (0.97–2.44) 0.067 - 1.65 (0.67–4.07) 0.278
* per: 1000/μL **: per IU/L ***: per 100 IU/L ****: per g/dLBMC Research Notes 2009, 2:157 http://www.biomedcentral.com/1756-0500/2/157
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reason for the differences between the previous and the
present results is unknown, but prior chemotherapy treat-
ment may adversely affect tumor response to gefitinib.
The incidence of ILD in this study was 3.2%, which is sim-
ilar to the values determined in other studies (3.5–5.8%)
(Table 4). Determining the incidence of anti-EGFR ther-
apy-related ILD in NSCLC is complicated by many factors,
including the underlying neoplastic disease, adverse
events caused by other chemotherapy agents, oxygen
treatment, radiation therapy, and opportunistic infec-
tions. In a study conducted by the West Japan Thoracic
Oncology Group (WJTOG) [23], the incidence of ILD in
gefitinib-treated NSCLC patients was found to be 3.5%. In
that study, ILD was defined as diffuse interstitial changes
or ground-glass appearance, and the diagnosis was con-
firmed on the basis of radiological findings and clinical
data by a central review committee comprising chest radi-
ologists, chest physicians, and oncologists. In the present
study, ILD was defined as a diagnosis of interstitial pneu-
monitis during gefitinib treatment, as diagnosed by each
institution on a clinical basis. A central review committee
was not involved. Despite this methodological difference,
the incidence of ILD in the present study population was
similar to the value found in the WJTOG study.
Risk factors for ILD have been identified in a number of
studies of Japanese gefitinib-treated NSCLC patients
(Table 4). In the present study, we also attempted to iden-
tify risk factors for ILD in gefitinib-treated NSCLC
patients, but unlike the previous studies, none of the fac-
tors we evaluated were found to be significant, including
sex, history of smoking, concurrent interstitial pneumoni-
tis, history of prior chemotherapy, and poor PS. We can-
not explain why this might be, but other risk factors that
we did not investigate may possibly be associated with
ILD.
In the interests of patient welfare, we need criteria by
which patients with factors predicting tumor response or
survival benefit and without factors predisposing to ILD
can be selected. In the WJTOG study it was concluded that
patient selection on the basis of female sex and the
absence of a history of smoking will increase the clinical
benefit of treatment with gefitinib and reduce the risk of
ILD [23]. In the present study, we found no factors that
clearly increase the benefit or decrease the risk. We did not
find an association between the predictive response prob-
ability and the occurrence of ILD. The mechanism by
which gefitinib might cause ILD is unclear, but that may
be because the site at which gefitinib acts is different from
that at which ILD manifests. Because of the considerable
risk to patients, further studies investigating risk factors
are warranted. The limitations of the present study were
the retrospective design, the relatively small number of
patients, and the conduction of the study using question-
naire, but the results of present study were similar to those
of the previous reports.
Table 3: Factors predicting tumor response (multivariate analysis)
Factor No. patients Odds ratio (95% CI) p-value
Sex
Male 256 1 -
Female 152 4.35 (2.40–7.90) <0.001
Prior chemotherapy
No 82 1 -
Yes 326 0.34 (0.18–0.65) 0.001
Absolute neutrophil count 408 0.85 (0.75–0.93)* 0.017
Histological type
Non-adenocarcinoma 127 1 -
Adenocarcinoma 281 2.35 (1.03–5.35) 0.043
Valuables with p < 0.05 were selected using a backward elimination procedure.
*per 1000/μL.
Relationship between predictive probability of tumor  response and ILD Figure 1
Relationship between predictive probability of tumor 
response and ILD.BMC Research Notes 2009, 2:157 http://www.biomedcentral.com/1756-0500/2/157
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Conclusion
The results of this study are consistent with previously
published values for treatment response proportions and
incidence of ILD during gefitinib treatment. In the inter-
ests of patient welfare, ILD in gefitinib-treated NSCLC
patients should be investigated further in large-scale pro-
spective studies, in which patients should be selected on
the basis of factors affecting ILD and predicting tumor
response.
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